pharmaphorum17h
Lynparza boosts long-term survival in early breast cancer
AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...
Medpage Today on MSN12h
HER2 Low and Ultralow Designations Open Door to Expansion of ADCs in Breast Cancer
A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase ...
AstraZeneca, Merck report positive long-term data for Lynparza
AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...
MedPage Today7h
Risk-Reducing Surgery May Benefit BRCA Carriers With Early-Onset Breast Cancer
Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...
The Pharma Letter1d
Lynparza on a roll with early breast cancer win
Lynparza demonstrates sustained survival benefits in Phase III OlympiA breast cancer trial, reducing death risk by 28% over ...
TMCnet14h
Novellia Data Shown to Optimize Risk Profiling to Inform HER2+ Breast Cancer Care
Project EVOLVE, funded by Daiichi Sankyo and AstraZeneca, to be presented at the 2024 San Antonio Breast Cancer Symposium -- NEW YORK, Dec. 12, 2024 /PRNewswire/ -- Novellia, Inc., an AI-enabled ...
With new data, Lilly sets pace for next wave of breast cancer drugs
While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...
mskcc.org1d
Imlunestrant Stops Progression of ER+, HER2- Advanced Breast Cancer That Resists Standard Therapy
An experimental drug stops advanced breast cancer from progressing in some people with tumors that have grown resistant to ...
Daily13d
Addition of AstraZeneca breast cancer drug Enhertu to China state insurance list
China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated sustained, clinically ...